This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.

⚠ Investigational / Not FDA-approved

The investigational medications discussed in this article — including retatrutide, survodutide, and cagrisema — are not FDA-approved for weight loss as of May 2026. They are in clinical trials and are not available for general prescription use. Information here is educational only — not a recommendation. Do not source medications from unverified suppliers.

The GLP-1 era transformed obesity treatment. Semaglutide (Wegovy) produced 15% body weight loss in clinical trials — more than any previous pharmacological approach. Then tirzepatide (Zepbound) eclipsed it with 21% average loss. The pharmaceutical industry's response: push further.

The next wave of metabolic medications moves beyond dual-agonism into triple-receptor activation and novel combination strategies. Early-phase data on some of these compounds suggests weight loss outcomes approaching 25–30% of body weight — numbers that begin to approximate outcomes from bariatric surgery, long considered the gold standard.

None of these drugs are approved yet. But understanding what's coming helps patients and clinicians make informed long-term treatment planning decisions and put current options in context.

Why Triple Agonism? The Scientific Logic

To understand next-gen drugs, it helps to understand what each incretin receptor does:

GLP-1 (glucagon-like peptide-1): - Stimulates insulin secretion - Suppresses glucagon (reducing liver glucose output) - Slows gastric emptying - Acts centrally to reduce appetite and food intake

GIP (glucose-dependent insulinotropic polypeptide): - Stimulates insulin secretion - Enhances GLP-1's effects on appetite when combined (as in tirzepatide) - May have direct effects on fat tissue, promoting fat mobilization - Reduces GLP-1-induced nausea (the GIP component in tirzepatide is partly responsible for its better GI tolerability profile)

Glucagon: - Primarily raises blood sugar (historically seen as a problem to suppress in diabetes treatment) - But: activates thermogenesis in brown adipose tissue, increases energy expenditure - In a metabolic context, controlled glucagon receptor agonism increases calories burned — the missing piece in pure appetite suppression

Adding glucagon receptor agonism to GLP-1 (and GIP) creates a triple threat: suppress appetite AND increase energy expenditure. This is the theoretical basis for triple agonists.

Retatrutide (Eli Lilly): GLP-1/GIP/Glucagon Triple Agonist

Retatrutide is Eli Lilly's triple agonist — activating GLP-1, GIP, and glucagon receptors. It is the most advanced triple agonist in clinical development as of 2026.

Phase 2 Results

In the Phase 2 dose-finding trial published in NEJM in 2023, retatrutide was evaluated in 338 adults with obesity (no diabetes) over 48 weeks:

  • 12 mg dose (highest): Average 24.2% body weight loss at 48 weeks — the largest 48-week weight loss result ever published for any pharmacological agent at that time
  • 8 mg dose: Average 22.8% body weight loss
  • 4 mg dose: Average 17.5% body weight loss
  • Placebo: 2.1% weight change

At 48 weeks, 26% of participants on the 12 mg dose had achieved ≥30% body weight loss — a threshold previously associated only with bariatric surgery.

What This Means

These results are striking for two reasons: 1. The absolute magnitude (~24%) is substantially larger than semaglutide (~15% at 68 weeks) and meaningfully larger than tirzepatide (~21% at 72 weeks) 2. The 48-week timeframe is shorter than the STEP and SURMOUNT trials — weight loss was still accelerating at the end of the trial

The Phase 3 program for retatrutide was initiated in 2024. Results are expected in 2026–2027. If Phase 3 data confirms Phase 2 findings, retatrutide could receive FDA review as early as 2027.

Safety Profile

Phase 2 retatrutide showed a similar GI side effect profile to tirzepatide (nausea, vomiting, diarrhea — mostly mild-to-moderate, declining over time). The glucagon component raised early concerns about effects on liver fat and blood glucose, but the trial data showed favorable lipid and glucose outcomes at therapeutic doses.

Survodutide (Boehringer Ingelheim / Zealand Pharma): GLP-1/Glucagon Dual Agonist

Survodutide is a GLP-1/glucagon dual agonist (no GIP component), co-developed by Boehringer Ingelheim and Zealand Pharma. Its glucagon:GLP-1 activity ratio is higher than retatrutide, meaning relatively more energy expenditure stimulation relative to pure appetite suppression.

Clinical Data

A Phase 2 trial published in The Lancet Diabetes & Endocrinology in 2023 reported:

  • 4.8 mg weekly dose: Average 18.7% body weight loss at 46 weeks
  • Comparable tolerability to GLP-1-only agents
  • Notable reduction in liver fat content — potentially relevant for MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD), which affects a large proportion of people with obesity

Survodutide received FDA Breakthrough Therapy designation for MASLD in 2024, reflecting significant unmet need in that indication. Phase 3 trials in obesity and MASLD are ongoing. The potential dual indication (obesity + liver disease) could make it particularly valuable for patients who have both conditions.

Cagrisema (Novo Nordisk): GLP-1 + Amylin Combination

Cagrisema is Novo Nordisk's combination of semaglutide (GLP-1 agonist) and cagrilintide (amylin analog), co-formulated as a single weekly injection. Unlike the triple agonists, cagrisema works via two entirely distinct hormonal pathways, potentially producing additive effects.

Amylin is a hormone co-secreted with insulin by pancreatic beta cells. It slows gastric emptying, reduces postprandial glucagon, and signals satiety through brainstem receptors distinct from GLP-1's sites of action. The amylin analog pramlintide (Symlin) is FDA-approved for diabetes but requires multiple daily injections.

Clinical Data

In the COMBINE 1 Phase 3 trial (published The Lancet, 2024):

  • Cagrisema (2.4 mg semaglutide + 2.4 mg cagrilintide): Average 22.7% body weight loss at 68 weeks in adults with obesity without diabetes
  • Semaglutide alone (2.4 mg): Average 16.1% in the same trial
  • Incremental benefit of adding cagrilintide: approximately +6.6 percentage points of additional weight loss

The mechanism works synergistically: semaglutide reduces food intake; cagrilintide adds additional satiety signaling through amylin pathways, slows gastric emptying further, and may independently suppress appetite via the area postrema. See our dedicated article on cagrisema and the amylin story for full trial detail.

Novo Nordisk submitted cagrisema for FDA review in late 2024. A decision is anticipated in 2026.

Other Pipeline Compounds Worth Watching

Orforglipron (Eli Lilly) — Oral GLP-1 Agonist

Orforglipron is a small-molecule oral GLP-1 receptor agonist — meaning it can be taken as a pill, not an injection. This is a significant access and adherence advantage. Phase 2 data showed ~14.7% body weight loss at 36 weeks. Phase 3 trials are ongoing; FDA review expected 2025–2026. Novo Nordisk's oral semaglutide (Rybelsus) exists but at low 14 mg doses with modest efficacy; orforglipron would be a step-change improvement.

Pemvidutide (Altimmune) — GLP-1/Glucagon Dual Agonist

Phase 2 data showed ~15.6% weight loss over 48 weeks with a favorable muscle preservation signal — meaning less lean mass lost per pound of total weight lost compared to GLP-1-only agents. Lean mass preservation is an emerging differentiator in next-gen compounds.

Mazdutide (Innovent/Eli Lilly China) — GLP-1/Glucagon

Strong Phase 2 data in Chinese populations; potential global development.

How to Think About These Drugs If You're Currently on a GLP-1

If you're currently on Wegovy or Zepbound and doing well, there is no reason to wait for next-gen compounds. The drugs available now have strong Phase 3 safety data, years of real-world use, and proven cardiovascular outcomes. Future drugs will have better efficacy data but less long-term safety evidence when they first launch.

For patients who: - Have achieved maximum results on current medications and want more - Have not responded to semaglutide and want to try a different mechanism - Have concurrent MASLD and obesity (survodutide may become a compelling option) - Have cardiovascular high-risk profiles and will benefit from more weight loss

...the pipeline is genuinely exciting. Clinical trial enrollment for Phase 3 retatrutide, survodutide, and other agents may also provide access for qualifying patients — search clinicaltrials.gov for current enrolling studies.

Independent Analysis: What the Pipeline Means in Practice

Three perspectives on the next-gen GLP-1 pipeline that get less attention than the headline weight-loss numbers:

1. The efficacy ceiling is approaching bariatric surgery territory

Roux-en-Y gastric bypass produces an average 25–30% body-weight loss at 1 year. Retatrutide's Phase 2 result of 24.2% at 48 weeks — with continued loss observed through the endpoint — suggests the next-gen agents will pharmacologically match or approach surgical outcomes. This shifts the clinical conversation for patients who would otherwise consider surgery. Cost, durability, and side-effect profiles will determine which path makes sense, but "surgery is necessary for >20% loss" is no longer accurate as of late 2025 trial data.

2. Triple agonism is not free

Glucagon agonism — the novel third pathway in retatrutide — increases energy expenditure but also raises heart rate and may modestly increase blood glucose at higher doses. The Phase 2 retatrutide paper reported mean heart rate increases of 5–8 bpm at the highest dose. For patients with cardiovascular disease, this is a meaningful consideration that the headline weight-loss number does not capture. The FDA review will scrutinize this. Expect a label that restricts use in certain cardiac populations.

3. Oral semaglutide changes adherence math

OASIS-1's 15.1% loss with oral semaglutide 25 mg matches injectable Wegovy. The clinical significance is not better outcomes — it is dramatically lower dropout rates. Injectable medication adherence at 12 months is 30–55% in real-world cohorts. Oral medication adherence in chronic disease is consistently 15–25 percentage points higher. That alone could shift average real-world outcomes upward even without efficacy gains. The patients who do not start, do not titrate up, or quit because of injection burden will have a much lower-friction option.

What to do now if you are interested in next-gen agents

For now, the practical options are: (1) stay on a currently approved GLP-1 and switch when the next-gen agents launch; (2) join an active clinical trial — see our retatrutide trial tracker for currently recruiting sites; (3) wait. Avoid unregulated compounded versions of investigational compounds like retatrutide, cagrilintide, and survodutide — these have not completed safety review and the compounded supply is operating in legal gray zones.

Frequently Asked Questions

When will retatrutide be available?

Eli Lilly initiated Phase 3 TRIUMPH trials in 2023. Pivotal results are expected 2026–2027, with FDA submission likely 2027 and commercial launch 2027–2028 if approved. Compounded versions exist now but are not FDA-evaluated and carry safety risk.

Is retatrutide really 'better' than tirzepatide?

Phase 2 data showed 24.2% weight loss at 48 weeks on retatrutide vs. 20.9% at 72 weeks for tirzepatide 15 mg in SURMOUNT-1. Direct head-to-head trials have not been published. Retatrutide also showed continued loss beyond the trial endpoint, suggesting the ceiling may be higher than the reported number.

What is the difference between CagriSema and Wegovy?

CagriSema combines semaglutide (the active ingredient in Wegovy) with cagrilintide, an amylin analog. The combination produced 22.7% weight loss vs. Wegovy's 14.9% in their respective trials. Novo Nordisk filed for FDA approval in early 2026.

Will oral semaglutide cost less than Wegovy?

Likely similar list price. Novo Nordisk has not announced pricing, but their pattern with oral Rybelsus suggests a comparable monthly cost to injectable. The savings come from injection-related costs (needles, sharps disposal, refrigeration logistics) and from improved adherence.

Are next-gen weight loss medications safer than current ones?

Not necessarily. They are new molecules with shorter post-marketing surveillance histories. Retatrutide's triple agonism introduces glucagon-related effects (mild heart rate increase, possible blood glucose elevation at high doses) that current GLP-1s do not have. Long-term safety data takes 5–10 years post-approval to accumulate.

Can I get retatrutide now through a compounding pharmacy?

Some compounding pharmacies offer 'research-use-only' retatrutide. This is investigational and not FDA-evaluated for safety or potency. The active ingredient has not completed Phase 3 review. Risks include unknown impurity profile, dosing inaccuracy, and absence of any patient-safety oversight. We do not recommend this path.

Sources

  1. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2)." NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301941
  2. Boehringer Ingelheim. "Survodutide Phase 2 OASIS Trial." Lancet Diabetes & Endocrinology, 2023. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00159-2/fulltext
  3. Novo Nordisk. "COMBINE 1 Phase 3 Trial: CagriSema vs Semaglutide." The Lancet, 2024. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02223-7/fulltext
  4. Wharton S, et al. "Orforglipron (LY3502970) Oral GLP-1 Agonist Phase 2 Results." NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2302392
  5. Joshi SR, et al. "Tirzepatide for Obesity (SURMOUNT-1)." NEJM, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  6. ClinicalTrials.gov. "Retatrutide Phase 3 Trials." https://clinicaltrials.gov/search?term=retatrutide